bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
1.119
-0.031 (-2.68%)
Dec 3, 2024, 1:05 PM EST - Market open
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $2.35M in the quarter ending September 30, 2024, with 687.44% growth. This brings the company's revenue in the last twelve months to $9.37M, up 2,813.87% year-over-year. In the year 2023, bioAffinity Technologies had annual revenue of $2.53M with 52,627.44% growth.
Revenue (ttm)
$9.37M
Revenue Growth
+2,813.87%
P/S Ratio
1.30
Revenue / Employee
$124,904
Employees
75
Market Cap
17.44M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
Dec 31, 2022 | 4.80K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBIAF News
- 19 days ago - bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 - Business Wire
- 4 weeks ago - bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development - Business Wire
- 4 weeks ago - bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung - Business Wire
- 6 weeks ago - WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement - PRNewsWire
- 6 weeks ago - bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement - Business Wire
- 6 weeks ago - WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement - PRNewsWire
- 6 weeks ago - bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement - Business Wire
- 6 weeks ago - bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines - Business Wire